Freestone Grove Partners’s Zimmer Biomet ZBH Stock Holding History

Freestone Grove Partners’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-925,937	Closed	-$91.2M	–	979
2025 Q3	$91.2M	Buy	925,937 +209,268	+29%	+$20.7M	0.68%	19
2025 Q2	$65.4M	Sell	716,669 -124,224	-15%	-$12M	0.49%	52
2025 Q1	$95.2M	Buy	840,893 +197,571	+31%	+$21.1M	0.98%	10
2024 Q4	$68M	Buy	+643,322	New	+$69M	0.83%	21

Other funds holding ZBH

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Freestone Grove Partners's ZBH Position: Q4 2025 in Review

Freestone Grove Partners sold out of Zimmer Biomet (ZBH) in Q4 2025, closing a stake of 925,937 shares — an estimated $91.2M sold.

Freestone Grove Partners first reported a position in ZBH in Q4 2024 and held it in 4 quarters. The position peaked at $95.2M in Q1 2025. 945 funds tracked by Wall St. Rank hold ZBH as of Q4 2025.

Freestone Grove Partners reported no remaining Zimmer Biomet position as of Q4 2025 after selling out during the quarter.
Freestone Grove Partners sold 925,937 Zimmer Biomet shares in Q4 2025, an estimated $91.2M.
Freestone Grove Partners first reported a position in Zimmer Biomet in Q4 2024 and held it in 4 quarters.
Freestone Grove Partners's Zimmer Biomet position peaked at $95.2M in Q1 2025.
945 funds tracked by Wall St. Rank held Zimmer Biomet as of Q4 2025.

Based on Freestone Grove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.